Welcome to this subway-themed activity where you can choose different subway lines for the education that is the most relevant to you. In this activity, John Anderson, MD, and Vivian Fonseca, MD provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM). Based upon the pathophysiologic rationale for combining basal insulin and a GLP-1RA, Drs. Anderson and Fonseca discuss the benefits and limitations of adding a GLP-1RA vs prandial insulin in patients with inadequate glycemic control with basal insulin.

Content Areas

  • Unmet needs
  • Experience with basal insulin/GLP-1RA
  • FRC basal insulin/GLP-1RAs
  • Insulin degludec/liraglutide (DUAL)
  • Insulin glargine/lixisenatide (LixiLan-L, -O)
  • Using FRC basal insulin/GLP-1RAs
  • Case studies

Target Audience

This activity is intended for primary care physicians, endocrinologists, nurse practitioners, nurses, pharmacists, and other clinicians with an interest in type 2 diabetes.

Faculty

Vivian A. Fonseca, MD
Vivian A. Fonseca, MD
Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana
John E. Anderson, MD
John E. Anderson, MD
The Frist Clinic
Nashville, Tennessee
Enter your information to begin.
CME Credit
Available Credit: 1.50 AMA PRA Category 1 Credits™.
1.50 ACPE Contact Hours
1.50 AANP Contact Hours
1.50 ANCC Contact Hours
Opens: October 05, 2018
Expires: October 04, 2019
Target Audience: Primary Care Physicians
Endocrinologists
Nurse Practitioners
Nurses
Pharmacists
Other Health Care Providers
This activity is supported by an educational grant from Novo Nordisk Inc.